ATXS
Price
$5.36
Change
-$0.08 (-1.47%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
302.49M
42 days until earnings call
FOLD
Price
$5.73
Change
-$0.20 (-3.37%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
1.76B
30 days until earnings call
Interact to see
Advertisement

ATXS vs FOLD

Header iconATXS vs FOLD Comparison
Open Charts ATXS vs FOLDBanner chart's image
Astria Therapeutics
Price$5.36
Change-$0.08 (-1.47%)
Volume$9.96K
Capitalization302.49M
Amicus Therapeutics
Price$5.73
Change-$0.20 (-3.37%)
Volume$255.69K
Capitalization1.76B
ATXS vs FOLD Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. FOLD commentary
Jul 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Buy and FOLD is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 01, 2025
Stock price -- (ATXS: $5.57 vs. FOLD: $5.93)
Brand notoriety: ATXS and FOLD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 265% vs. FOLD: 185%
Market capitalization -- ATXS: $302.49M vs. FOLD: $1.76B
ATXS [@Biotechnology] is valued at $302.49M. FOLD’s [@Biotechnology] market capitalization is $1.76B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileFOLD’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • FOLD’s FA Score: 0 green, 5 red.
According to our system of comparison, ATXS is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 5 TA indicator(s) are bullish while FOLD’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 5 bullish, 5 bearish.
  • FOLD’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, FOLD is a better buy in the short-term than ATXS.

Price Growth

ATXS (@Biotechnology) experienced а -4.95% price change this week, while FOLD (@Biotechnology) price change was +5.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.68%. For the same industry, the average monthly price growth was +32.84%, and the average quarterly price growth was +6.72%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

FOLD is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+3.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($1.76B) has a higher market cap than ATXS($302M). FOLD (-37.049) and ATXS (-37.696) have similar YTD gains . FOLD has higher annual earnings (EBITDA): 53.6M vs. ATXS (-124.4M). ATXS has more cash in the bank: 295M vs. FOLD (251M). ATXS has less debt than FOLD: ATXS (5.06M) vs FOLD (443M). FOLD has higher revenues than ATXS: FOLD (543M) vs ATXS (0).
ATXSFOLDATXS / FOLD
Capitalization302M1.76B17%
EBITDA-124.4M53.6M-232%
Gain YTD-37.696-37.049102%
P/E RatioN/AN/A-
Revenue0543M-
Total Cash295M251M118%
Total Debt5.06M443M1%
FUNDAMENTALS RATINGS
ATXS vs FOLD: Fundamental Ratings
ATXS
FOLD
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9693
PRICE GROWTH RATING
1..100
5388
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (59) in the Biotechnology industry is in the same range as FOLD (64). This means that ATXS’s stock grew similarly to FOLD’s over the last 12 months.

ATXS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as FOLD (100). This means that ATXS’s stock grew similarly to FOLD’s over the last 12 months.

FOLD's SMR Rating (93) in the Biotechnology industry is in the same range as ATXS (96). This means that FOLD’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's Price Growth Rating (53) in the Biotechnology industry is somewhat better than the same rating for FOLD (88). This means that ATXS’s stock grew somewhat faster than FOLD’s over the last 12 months.

ATXS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as FOLD (100). This means that ATXS’s stock grew similarly to FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSFOLD
RSI
ODDS (%)
Bearish Trend 4 days ago
82%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
72%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
78%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
66%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 15 days ago
79%
Bullish Trend 4 days ago
68%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 13 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
77%
Aroon
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGEFX14.640.14
+0.97%
Baillie Gifford International Growth 4
SCIIX7.330.07
+0.96%
Virtus SGA International Growth A
ESGEX20.810.15
+0.73%
Reynders McVeigh Core Equity Instl
VGSNX19.420.06
+0.31%
Vanguard Real Estate Index Institutional
MTODX21.860.03
+0.14%
NYLI Income Builder Class R6

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with XENE. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+2.39%
XENE - ATXS
53%
Loosely correlated
+0.62%
CRNX - ATXS
52%
Loosely correlated
-1.48%
ERAS - ATXS
52%
Loosely correlated
+3.97%
DNLI - ATXS
52%
Loosely correlated
-2.69%
COGT - ATXS
52%
Loosely correlated
-3.14%
More